Top Qs
Timeline
Chat
Perspective
Abelacimab
Monoclonal antibody From Wikipedia, the free encyclopedia
Remove ads
Abelacimab (MAA868), is a fully human monoclonal antibody for the treatment of thrombosis,[1] under development by Anthos Therapeutics.
Remove ads
Mechanism of action
It is anti-factor XI antibody. The hope behind its developoment is that factor XI plays a bigger role in thrombosis (via the intrinsic/contact activation pathway) than hemostasis, so targeting it might reduce clotting risks without a corresponding increase in bleeding.[1] It has, indeed, shown overwhelming reduction in bleeding as compared to a direct oral anticoagulant (rivaroxaban) in patients with atrial fibrillation and a moderate-to-high risk of stroke.[2] Data is insufficient for drawing a conclusion on whether it increases or decreases stroke events as compared to rivaroxaban.[3]
Remove ads
See also
References
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads